Treatment of Alopecia Areata With Tofacitinib | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Xing  L, Dai  Z, Jabbari  A,  et al.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.  Nat Med. 2014;20(9):1043-1049.PubMedGoogle ScholarCrossref
Jabbari  A, Nguyen  N, Cerise  JE,  et al.  Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.  Exp Dermatol. 2016;25(8):642-643.PubMedGoogle ScholarCrossref
Kennedy Crispin  M, Ko  JM, Craiglow  BG,  et al.  Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.  JCI Insight. 2016;1(15):e89776.PubMedGoogle ScholarCrossref
Olsen  EA, Hordinsky  MK, Price  VH,  et al; National Alopecia Areata Foundation.  Alopecia areata investigational assessment guidelines—part II.  J Am Acad Dermatol. 2004;51(3):440-447.PubMedGoogle ScholarCrossref
Xeljanz [package insert]. New York, NY: Pfizer; 2016.
Mackay-Wiggan  J, Jabbari  A, Nguyen  N,  et al.  Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.  JCI Insight. 2016;1(15):e89790.PubMedGoogle ScholarCrossref
Research Letter
June 2017

Treatment of Alopecia Areata With Tofacitinib

Author Affiliations
  • 1Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio
JAMA Dermatol. 2017;153(6):600-602. doi:10.1001/jamadermatol.2017.0001

Tofacitinib citrate is a Janus kinase 1/3 inhibitor approved for the treatment of rheumatoid arthritis, but it has recently been used to treat alopecia areata (AA).1-3 In this study, investigators searched the medical records of the Cleveland Clinic for any patients with confirmed AA who were treated with oral tofacitinib (Xeljanz; Pfizer) using a standardized, systematic treatment regimen.

A standard departmental treatment protocol was developed prior to this review. Treatment with tofacitinib citrate was initiated at 5 mg twice daily, and all other AA therapies were ceased. The daily dosage was increased, as allowable by insurance coverage, by 5 mg per month until the treating physician noted first signs of hair regrowth and then held the medication at that dose. The Cleveland Clinic Foundation Institutional Review Board approved this retrospective medical record review and waived the patient informed consent requirement. The review took place from May 1, 2016, to June 1, 2016.